Christopher SchottPartner at Latham & Watkins
Christopher H. Schott primarily advises on price reporting and other compliance obligations related to the Medicaid, Medicare, and 340B drug pricing programs. He combines extensive regulatory insight with deep industry knowledge to support pharmaceutical clients at all stages of the market access and product life cycle. In addition to advising on methodologies and reasonable assumptions that support the periodic certification and submission of pricing data, Chris also helps pharmaceutical manufacturers proactively engage with federal regulators through in-person advocacy. He also frequently advises drug manufacturers seeking guidance from regulators regarding specific issues or commercial proposals.